Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dems' 'Better Deal' Would Create Drug Price Gouging 'Enforcer'

Executive Summary

Plan would empower new agency to investigate and potentially fine drug manufacturers that make unjustified price increases.

Advertisement

Related Content

Generic Industry Sues To Halt Maryland's 'Price Gouging' Law
FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit
The Bully Pulpit: Trump Versus Drug Prices
Formalizing 'Name And Shame': New Strategy To Rein In Price Increases
The Clinton Drug Price Board, 23 Years Later
EpiPen Price Story Highlights Growing Impact Of Drug Deductibles
Drug Price Control Proposals Pared Down In Democrats’ Draft Platform
Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel